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Abstract
Analyzing different drugs for various purposes is an important issue in the
area of computational biology. We categorize the previous computational
studies into Individual and Network approaches. While the Individual ap-
proach focuses on one specific drug without considering its relationship with
other drugs, the Network approach considers also the drugs relationships. In
this paper, we apply a Network approach, previously proposed for discover-
ing the relationships among diseases, to drug data. We construct a Human
Drug Network (HDN) for 200 different drugs based on functional and struc-
tural information available in the PPI network. For evaluating our proposed
HDN, first, we analyzed the literature to prove that the proposed HDN is
biologically meaningful. Second, we used the HDN to augment the initial
prior knowledge of different drugs. As an example of prior knowledge, we
considered the initial seed proteins (a set of proteins which are previously
known to be drug targets) of each drug. We clustered the HDN nodes using
the Markov CLustering Algorithm (MCL) and then, we augmented the seed
proteins of each drug based on the cluster it belongs to. In the end, we con-
cluded that our proposed HDN enables us to generate novel hypotheses (in
terms of potential drug target proteins) and produce complementary results
comparing to existing methods.
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1. Introduction
In recent years, much effort has been invested in the construction of
protein-protein interaction (PPI) networks [1]. Much can be learned from
the analysis of such networks with respect to the metabolic and signal-
ing processes present in an organism, and the knowledge gained can also
be prospectively employed e.g., for the task of protein function prediction
[2, 3, 4], identification of functional modules [5], interaction prediction [6, 7],
identification of disease candidate genes [8, 9, 10, 11, 12, 13, 14, 15, 16, 17]
and drug targets [18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31], according
to an analysis of the resulting network [32].
It is estimated that a typical drug discovery cycle, from target identifica-
tion to clinical use, can take 14 years [33] with cost of 800 million US dollars
[34]. Recently, computational methods have been widely applied to facilitate
the design and discovery of new drugs [35]. Identification of new drug target
proteins is the first and still very important step in the drug discovery cycle
[36]. Although computational methods can not substitute the real screen-
ing targets of a novel drug, they succeed to lower the costs and time in all
steps of the drug discovery cycle. They investigate huge amounts of chemical
compounds which may have not been synthesized before [37] and then, they
generate novel hypotheses about newly-identified drug target proteins and
accordingly, reduce the initial number of compounds for the experimental
analysis.
We categorize the previous computational studies on drug-target identi-
fication into Individual and Network approaches. The Individual approach
focuses on one specific drug without considering its relationship with other
drugs. Methods implementing this approach usually transform different
properties of target proteins into numeric features and then, they apply com-
putational methods to detect potential drug-target interactions [18, 19, 32,
38, 39, 40, 41, 42, 43]. The main difference among the Individual methods
lies in the type of properties they consider for the prediction. Complemen-
tary to Individual approach, the Network approach first discovers the hidden
relationship among different drugs, and then it uses this information to pre-
dict novel drug target proteins by sharing information across highly-related
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drugs [29, 44, 45, 46, 47]. The main assumption behind the Network ap-
proach is that similar drugs tend to target similar proteins [48, 49]. The
method proposed by Yildirim et al., [29], which has a prominent role among
the network based approaches, connects two drugs in the network if they
share at least one target protein. However their approach is not capable of
discovering relationships among drugs with no common target proteins. In
this paper, we apply the existing Network approach for discovering the re-
lationships among diseases [50] on drug data. In the resulting network, two
drugs even with no common target proteins may be connected to each other if
they are found to be similar with respect to contextual information extracted
from PPI networks. Once the Human Drug Network (HDN) is constructed,
the information in the HDN can be used to generate novel hypotheses about
drug targets, identifying genes that may be involved in some drugs but would
not be detected using previous approaches.
Section 2 discusses the previous methods on drug target prediction. We
describe the network approach in detail in Section 3. In Section 4, the method
is applied to a concrete PPI network; using functional and structural infor-
mation from the network, a drug network is constructed for 200 drugs. This
network is next evaluated in terms of interpretability and knowledge aug-
mentation. Section 5 concludes.
2. Background
The identification of relations between drugs and their target proteins is
a key area in drug discovery cycle [36]. Complementary to high-throughput
screening methods, computational approaches are used extensively to reduce
costly late-stage drug failures and accelerate successful development of new
drugs.
For the task of drug target prediction, existing computational approaches
could either focus on each drug individually and neglect the relationships
among drugs [18, 19, 32, 38, 39, 40, 41, 42, 43] or they could consider the
informative relationships among the highly-related drugs in the prediction
process [29, 44, 45, 46, 47]. The former and the latter approaches are called
Individual and Network approaches, respectively.
The Individual approach predicts drug targets for a individual drug ac-
cording to the drug’s informative features. Zoraghi et al., [18] argue that the
architecture of bacterial or hostpathogen protein interactomes can provide in-
valuable insights for the identification of novel antibacterial drug targets. De
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Las Rivas et al., [19] find novel drug targets according to the location of the
proteins in the interactome network. Maayan et al. [32] constructed a bipar-
tite network connecting drug targets and drugs and subsequently analyzed
the targets in the context of a global protein-protein interaction network.
Keiser et al., [38] compare 3,665 US Food and Drug Administration (FDA)-
approved and investigational drugs against hundreds of targets, defining each
target by its ligands and then they predict thousands of unanticipated as-
sociations according to chemical similarities between drugs and ligand sets.
Campillos et al., [39] predict new targets for established drugs looking for
side-effects shared between two molecules. Kolarik et al., [40] developed an
approach for the identification of new terms used in unstructured text that
provide information about drug properties. Hert et al., [41] build target re-
lationships based on the structural and biological similarity of their ligands.
Hwang et al., [42] propose an approach for identifying ’bridging nodes’ in the
biological network as potential drug targets. Bleakley et al., [43] introduce
a Bipartite Local Models (BLM) to first predict target proteins of a given
drug, then to predict drugs targeting a given protein.
The Network approach, mostly, assumes that similar drugs tend to target
similar proteins [48, 49]. Yildirim et al., [29] connect two drugs if they share
a common target. They show that most new drugs interact with previously
targeted cellular components and there are relatively few drugs entering the
market with novel targets. There is a family of methods which use chemical
structural information to build drug-drug relationships [44, 45, 46, 47]. They
first convert the chemical structure into numerical vectors and then define
the drug-drug relationship according to vector similarity.
3. Materials and Methods
3.1. Terminology and Symbols
We consider a PPI network as an undirected annotated graph (P,E, λF , λD)
where P is a set of proteins, E ⊆ P ×P is a set of interactions between these
proteins, and λF and λD are so-called annotation functions; for each protein
p, λF and λD denote additional information we have about p. λF (p) lists
all the GO functions that are associated with p; we call it the function set
(or function vector) of p, and denote it FS(p). λD(p) lists all the drugs that
target protein p; we call it the drug list of p and denote it drugList(p). We
also define seed proteins SP (di) as the set of proteins targeted by drug di
(di ∈ drugList(p)⇔ p ∈ SP (di)).
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3.2. Human Drug Network
We now describe our method for building a Human Drug Network (HDN)
from a PPI network. Essentially the same method was used before to con-
struct human disease networks, with good results [50]. We define a Human
Drug Network (HDN) as a directed graph HDN(D,R) where D is a set of
drugs and R ⊆ D×D is a set of directed relationships between these drugs.
We build our proposed HDN as follows.
For each drug di, we learn a model that can predict, for any protein p, how
likely p is targeted by this drug. Next, we use this model to make predictions
for all the seed proteins of a drug dj. The higher these seed proteins score,
on average, the stronger the link between di and dj is considered to be.
Concretely, the model for a drug di is learned and used as follows:
1. let testSet contain the seed proteins of all drugs except di.
2. let trainSet contain all proteins not in testSet
3. We learn a predictive model M from trainSet, using the seed proteins
of di as positive examples and all other proteins as negative examples.
We then use M to predict for each protein in testSet how likely it is
targeted by di (higher values meaning more likely). For randomized
learners, we repeat this 10 times (otherwise just 1 time) and calculate
for each p ∈ testSet the average, denoted APV (p).
4. For each drug dj ∈ D(j 6= i), we add a directed edge di → dj to the
HDN with a weight
weight(di → dj) =
∑
p∈SP (dj)APV (p)
|SP (dj)| (1)
with |SP (dj)| the number of seed proteins of dj.
This procedure is repeated for all drugs. The resulting HDN is a directed,
fully connected network in which each node is a drug and each weighted edge
shows a relationship between two drugs. A high weight for di → dj expresses
that proteins targeted by dj are, on average, likely to be targeted also by di,
according to the model built for di.
In order to focus on the most important relationships in the HDN, we
prune the network by keeping only the highest-ranked edges. Section 4.2
discusses the pruning procedure of the original network in details.
There are many ways in which the predictive model M can be learned
from the PPI network (step 3). Based on the study on the same PPI dataset
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[50], we choose a hybrid prediction method which considers both Structural
and Functional information in the PPI network. We discuss this method in
the next section.
3.3. Hybrid Prediction Method
Rahmani et al., [50] analyzed different functional and structural predic-
tion methods and they observed that a hybrid method that considers both
functional and structural information in the PPI network worked best for
building the Human Disease Network. In this paper, we use the same predic-
tion method for building Human Drug Network. The following section de-
scribes the proposed structural, functional and the hybrid prediction methods
in details.
3.3.1. Structural Information (ST-RW)
Berger et al. [51] propose a random walk based approach to predict
disease-related proteins in PPI networks. They assume that disease-related
proteins fall closer, with respect to average number of steps a random walker
takes to walk from a specified protein to another one, to the seed proteins
than they do on average to the rest of the proteins in the PPI network. They
calculate the score of each protein pj in the PPI network based on Formula
2 and then, select high-scoring proteins as disease-related proteins.
scores(pj) =
∑
i∈C′ Tij
|C′| −
∑
i∈C Tij
|C|∑
i Tij
|C|+|C′|
(2)
In Formula 2, Tij is the average number of steps a random walker takes
to walk from a specified node i to another specified node j, C is the set of
seed proteins and C ′ is the set of all other proteins in the network. In the
rest of this paper, we refer to this method as ST-RW.
3.3.2. Functional Information (Func-Indiv)
This method uses the functional annotations of proteins. For each func-
tion, it determines how strongly the function correlates with drug-target
relatedness, using the standard χ2 statistic as proposed by Liu et al. [52]:
χ2(fi) =
(ad− bc)2 ∗ (a+ b+ c+ d)
(a+ b)(c+ d)(b+ d)(a+ c)
(3)
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where a = |D ∩ Pi|, b = |D ∩ P¯i|, c = |D¯ ∩ Pi|, and d = |D¯ ∩ P¯i|, with Pi
and P¯i the set of proteins labeled and not labeled with function fi, and D
and D¯ the set of drug-target and not drug-target proteins, respectively.
Next, it describes all proteins using the highest-scoring functions as fea-
tures, and then a standard machine learning system can be used to learn a
model that from these informative features predicts the likelihood of involve-
ment. We here use Naive Bayes [53]. This method estimates the conditional
probability distribution for the variable to be predicted, given the feature
values, and up to a constant factor, as follows:
p(C|F1, . . . , Fn) ∼ p(C)p(F1|C)p(F2|C) · · · p(Fn|C) (4)
This estimation of the conditional probability distribution relies on con-
ditional independence of the features given the target. This assumption is
usually violated, but the method is quite robust to violations of the assump-
tion [54], and works well in practice. Furthermore, several researchers found,
in a similar context, that the features are more important than the actual
machine learning method used [55]. In the rest of this paper, we refer to this
method as Func-Indiv.
3.3.3. Integrating Functional and Structural Information
Structural-based and functional-based methods can be combined into a
hybrid method. The hybrid method is calculated as follows:
scoreh(p) = norm(scores(p)) + norm(scoref (p)) (5)
In Formula 5, scores(p) and scoref (p) represent the drug-relatedness score
of p using a Structural (ST-RW) and a Functional (Func-Indiv) method,
respectively. In order to avoid a bias toward either of these categories, we
normalize the drug-relatedness scores using
norm(xi) =
xi −min(x)
max(x)−min(x) (6)
where min(x) and max(x) return the minimum and maximum values taken
over all values of x, respectively. In the rest of this paper, we refer to this
method as RW-Indiv.
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4. Empirical Results and Discussion
In this section, we discuss several aspects of the proposed method in more
detail, and investigate them experimentally.
The dataset used for the experiment is described in Section 4.1. In Sec-
tion 4.2, we show the HDN constructed by our method, and provide a bio-
logical interpretation; this is meant as an evaluation of how informative and
interpretable the network is. Finally, a more objective type of evaluation
is: How useful is the HDN from the point of view of predicting drugs tar-
gets? Does using the network yield better predictions? In section 4.3, we
augment the initial seed proteins of different drugs by sharing information
across highly-related drugs. Then, we evaluate the use of augmented seed
proteins for predicting drug target proteins in two different ways.
4.1. Dataset
We applied our method for building the HDN to the PPI network used
by Milenkovic et al. [56]. This dataset is the union of three human PPI
datasets: HPRD [57], BIOGRID [58] and the dataset used by Radivojac et
al. [59] and contains 47, 303 physical interactions among 10, 282 proteins.
When we say “union”, we mean that the new network contains all the nodes
and edges (proteins and interactions) found in either of these networks. The
aim of merging these three datasets was to obtain as complete a human PPI
network as possible, i.e., a network that covers with its edges as many proteins
in the human proteome as possible. Milenkovic et al. [56] provide details on
the construction of the integrated network. The GO functions of proteins are
extracted from [60]. Table 1 shows some basic statistical information about
our annotated dataset.
We analyzed 200 drugs from the DrugBank [61] database. Table 2 shows
the 20 drugs with the highest number of seed proteins. The average number
of seed proteins for all 200 drugs is 11.51. The list of 200 drugs with their seed
proteins is listed in http://www.liacs.nl/~hrahmani/HDN/drugtargets.
html
4.2. Novel Human Drug Network
The hybrid prediction method discussed in Section 3.3 rely on a feature
selection step, for which a number of features needs to be decided. Based on
earlier work on the same dataset [62], we consistently choose 100 functional
and 10 structural features. Having made this choice, we build our proposed
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HDN for 200 different drugs. There are 39800 (200× 199) possible edges in
the original HDN. Each edge di → dj shows the average rank of seed proteins
of dj among all the proteins in the Test set using the seed proteins of di as
positive examples in the Train set. Train and Test sets are both described in
Section 3.2. The lower average rank indicates stronger relationship between
di and dj, in comparison with other drugs. To select the most informative
relationships among drugs, first, we sort the edges according to their score
(average rank of seed proteins), ascendingly. The result is shown in Figure
1. In this figure, the X axis shows the 39800 edges in the HDN and the
Y axis shows, for each edge di → dj, the average rank of the seed proteins
of dj (the smaller, the better). Second, we determine the candidate cutoff
points by discovering two turning points in the curve, roughly at 3% and
86% of all edges. Finally, instead of analyzing the whole HDN, we focus on
the pruned HDN containing only the 1328 (3% of the original HDN) highest-
ranked edges. This turns the fully-connected graph into a more informative,
visualizable graph.
Figure 2 shows the pruned HDN using cytoscape [63]. Then, to discover
highly-related drugs in the pruned network we cluster the pruned HDN using
the Markov Clustering (MCL) [64]. We should emphasize that in our pruned
Human Drug Network, each edge shows an informative relationship between
two drugs and accordingly, the clustering method should focus on network
connections as main indicators of related drugs. The key intuition behind
Markov Clustering (MCL) [64] is that a “random walk that visits a dense
cluster will likely not leave the cluster until many of its vertices have been
visited”. MCL has been applied in a number of different domains, mostly in
bioinformatics [65, 66, 67, 68]. Figure 3 and Table 3 represent 13 clusters ex-
tracted from the pruned network using MCL clustering in graph and tabular
formats, respectively.
We will now briefly discuss the biological significance of the observed
findings in Figure 2. Clearly visible are, from left to right, firstly a group
of both strong painkillers and hypnotics (e.g. tramadol) and analogues of
ephedrine. This group also contains many compounds with high abuse po-
tential (amphetamines, cocaine, tramadol) which often work on the opinion
receptors, as well as the serotonin transporter system. The next large group,
containing e.g. methamphetaime, moves away from activity on the opioid
receptors, and generally to more polypharmacology again neurotransmitter
transporters. The ethchlorvynol group that comes next is a classical hyp-
notics group, with barbital action generally being allosteric modulation of
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GABA-A receptors. It is interesting - and correct - to note that the benzodi-
azepine group is located next to it (containing e.g. diazepam, better known
under its trade name Valium) and hence strongly linked via the biological
targets modulated; however, separation is not complete (e.g. Aprobarbital
is here contained within the benzodiazepine group). The following - dis-
joint - group is concerned with matrix remodeling, involving proteins such
as urokinase (as well as Vitamin C, where lack of it is known to involve tis-
sue disorder, scorbut). Further group contain kinase inhibitors used to treat
cancer (e.g. dasatinib), as well as an antibody group (containing e.g. etan-
ercept). Hence, overall, we can conclude that both the groups themselves, as
well as their relationships to groups involving similar biological processe, are
overall biologically rather meaningful.
In addition to known bioactivities for drugs, after applying the MCL algo-
rithm to clustering drugs, a different - and possibly cleaner - picture of drug
bioactivity emerges. This picture could provide insights for exploring the
new aspects of drug bioactivities. As shown in Figure 3, both barbiturates
and diazepams now cluster together (Cluster 1 in Table 3), which is under-
standable given that both act to a good extend on the GABA-A receptor.
Also drugs working on other GPCRs in the brain (a well as neurotransmit-
ter transporter, such as the one of dopamine and serotonin) show a cleaner
cluster, as indicated as the next cluster (Cluster 2 in Table 3). While the
kinase antibodies (Cluster 3 in Table 3) cluster also here, the same is interest-
ingly not true for small-molecule kinase inhibitors: Here the sunitinib cluster
(Cluster 6 in Table 3) contains both small molecule inhibitors of kinases as
well as Adenosine Triphosphate (which is required for kinase activity), and
also the group of tramadol and cocaine which could be seen in Figure 2 is
now not present anymore.
4.3. Prediction from Augmented Seed Proteins
We now consider the task of drug target hypotheses generation, using a
predictive model learned from data. The quality of such a predictive model
obviously depends on the prior knowledge incorporated in the data. While
earlier models focused on knowledge about one drug, we hypothesize that
augmenting the prior knowledge about one drug with knowledge obtained
from studying related drugs may yield better predictive models.
To evaluate this hypothesis, we have used our proposed HDN for aug-
menting the seed proteins of different drugs as follows.
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First, we clustered the pruned HDN into n clusters C1 . . . Cn using MCL
clustering. The reason we chose MCL clustering and the biological mean-
ingfulness of cluster results are all discussed in Section 4.2. Second, we aug-
mented the seed proteins of each drug by adding the seed proteins of all the
drugs in the same cluster Cj; that is, di ∈ Cj ⇒ Aug(di) = ∪dk∈CjSP (dk),
with Aug(di) the augmented list of seed proteins of drug di.
Next, we have evaluated the effect of using the augmented list to learn a
model, instead of the original list, along two dimensions: predictive accuracy,
as well as biological meaningfulness.
First, we compare the predictions of a model learned using augmented
seed proteins (Network approach) with those of a model learned using only
the initial seed proteins (Individual approach). In both cases, the same
learning method was used (RW-Indiv).
Figure 4 compares the Network approach with the Individual approach
for 13 drug clusters augmented by our HDN, in terms of the following leave-
one-out cross-validation procedure, proposed earlier by De Bie et al. [69].
For each cluster cj
1. For each drug di ∈ cj:
(a) Randomly select 99 proteins that are not seed proteins for di
(b) For each seed protein p of di:
i. let testSet contain p and the 99 proteins
ii. let trainSet contain all other proteins
iii. Learn a model M from trainSet, apply it to testSet, and
check how high p ranks.
(c) Repeat steps 1a to 1b ten times and calculate the average rank
AR(p) of each seed protein p. The overall rank of di, for a given
method, is then defined as
overallRank(di) =
∑
p∈SP (di)AR(p)
|SP (di)| (7)
2. Finally, calculate the average rank of cluster cj using Formula 8.
AverageRank(cj) =
∑
di∈cj overallRank(di)
| ∪di∈cj |
(8)
where | ∪di∈cj | returns the number of drugs belong to cluster cj.
The comparison result is shown in Figure 4. The Network approach
outperforms the Individual approach in clusters 2, 6, 10 and 12 with 39, 7, 4
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and 2 drug members. In total, the Network approach predicts more accurate
results in 26% (52 drugs) of the 200 considered drugs. This suggests that our
proposed Network approach should not be seen as replacing the Individual
approach, but as complementary to it.
Beside the numerical evaluation mentioned above, we also want to eval-
uate to what extent the proposed network approach predicts biologically
meaningful results. To this aim, we ask the domain experts to biologically
interpret the proteins predicted to be targeted by drugs even when they were
not annotated as such in the training data. Our approach consists of the
following steps: First, we build a new training set containing the augmented
list of seed proteins (positive set) in addition to 100 randomly selected pro-
teins (negative set). Even though we are not sure that all of these random
proteins are negative, it is very likely that the majority of them are negative.
The remaining positive cases constitute noise in the training set. Second, we
build a test set containing all the remaining proteins in the network. Third,
we use RW-Indiv for predicting new proteins targeted by drugs. Table 4
shows 10 highest-ranked proteins predicted for each cluster shown in table 3.
In table 4, clear differences as to the bioactivity profiles of the different
clusters can be observed. Cluster 1 is a classical GPCR cluster, with activity
involving both serotonin and nicotinic acetylcholine receptors. Cluster 2
is related, however containing the adenosine receptors as GPCR receptors,
as well as the glutamate and alpha subtypes of the nicotinic acetylcholine
receptors. With cluster 3 we are moving into the area of peptide receptors,
such as DPP4 and CCL5. Targets in cluster 4 are related to metabolism (e.g.
APOE), as well as blood coagulation (THBS1, FGB) which is consistent with
the drugs that belong to this cluster. Cluster 5 is a very different cluster,
namely use that contains a large number of six different isoforms of the
metabolizing enzyme P450, but also other related proteins (e.g. pyruvate
carboxylase). In cluster 6 we move to more cancer-related targets, involving
both oncogenes (e.g. AKT2), as well as growth factors (TGFBR2). While
cluster 7 is difficult to get a homogeneous picture of, cluster 8 is very much
dominated by the dopamine receptor subtypes (D1-D4), which are classical
targets of antidepressants or, more general, CNS-active drugs. Cluster 9
also contains some of the dopamine receptors (namely D1-D3) however it
also has as the highest-ranked target the serotonin 1B receptor (HTR1B)
on the list. Cluster 10 is significantly different in nature - it contains solely
ribosomal proteins, so those involved in protein synthesis. While cluster 11
contains both potassium and calcium channels (many of which are involved
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in the action potential of the heart), cluster 12 contains also ion channels,
but mostly different ones from the ones in the previous cluster. The same
can be said about Cluster 13, which now involves also a variety of sodium
channels in addition to the above.
The biological meaningfulness of the result confirms the possibility of
using the proposed Human Drug Network for generating other types of novel
hypotheses for drugs. For example, we could investigate whether the co-
clustering drugs in the Human Drug Network share similar side-effects or
not.
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5. Conclusions and Future Work
The previous studies on analyzing different drugs can be categorized into
the Individual and Network approaches. While the Individual approach fo-
cuses on one specific drug without considering its relationship with other
drugs, the Network approach considers also the drugs relationships. In this
paper, we examine a previous Network approach for discovering the relation-
ships among diseases [50] on drug data and we showed that our method is
capable of generating novel hypotheses (in terms of complementary drug tar-
get proteins) by considering the informative relationships among drugs. We
built an HDN for 200 different drugs. The discovered relationships among
drugs were biologically discussed and validated by domain expert. Then, we
clustered the HDN nodes using Markov CLustering Algorithm (MCL) and
we augmented the seed proteins of drugs based on the cluster they belong to.
Finally, we compared the predictions of models learned using the augmented
list with those of models learned using the original list. We observed that our
proposed method outperforms the Individual approach in 26% (52 drugs) of
the 200 considered drugs.
As future work, we could improve and extend the proposed method in
several directions. In the first direction, we could apply more extensive val-
idation to the result of our proposed approach. We have already discussed
and validated our results in sections 4.2 and 4.3 by domain expert, however,
biological/experimental validation of the findings using methods such as PR
and RT-PCR is still challenging and needs separate studies. Additionally,
although we believe strongly that the results of this paper reduce the search
space, generate novel hypotheses and bring new insights for the biologists
and clinical researchers, these results should not be assumed as effective and
employed in action by pharmaceutical companies unless they are validated
experimentally in the laboratories. In the second direction, in addition to
functional and structural features, we could consider other biological features
in the system. In the third direction, we could investigate the complementar-
ity nature of our proposed network approach in more depth. For instance, we
could compare the proteins predicted by the Network approach (as listed in
Table 4) to those predicted by the individual approach and then discuss the
targets that were discovered by the network approach but missed by the indi-
vidual approach. In the fourth direction, we could use the proposed Human
Drug Network for generating other types of novel hypotheses. For example,
co-clustering in the Human Drug Network may suggest some similarities in
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pharmacodynamics of the drugs. It may generate novel hypothesis on a new
drug indication. In addition, co-clustering may suggest some similarities in
pharmacologic profiles of drugs. These include pharmacokinetic properties,
drug interaction as well as side effect profiles.
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6. Tables
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Table 1: Basic statistical information about our annotated dataset.
Number of Proteins 10,282
Min Degree 1
Max Degree 272
Average Degree 9.39
Number of Proteins with no Function 1519
Average Number of Functions for each Protein 10.40
24
Table 2: 20 drugs with the highest number of seed proteins.
DrugName Seed Count
NADH 77
L Glutamic Acid 49
Adenosine triphosphate 30
Alpha D Mannose 29
Adenosine 5 Diphosphate 25
Clozapine 24
Quetiapine 24
Aripiprazole 23
Ziprasidone 23
Olanzapine 23
Nicotinamide Adenine Dinucleotide 23
Pyridoxal Phosphate 23
Amitriptyline 19
Marimastat 19
Glycine 18
Doxepin 18
Bromocriptine 18
Temazepam 17
Pergolide 17
Lorazepam 17
25
Table 3: 13 clusters extracted from the pruned network using MCL clustering [64].
Cluster ID Cluster Members
Cluster 1 Nitrazepam, Halazepam, Oxazepam, Heptabarbital, Hexobarbital, Ethchlorvynol,
Nicotine, Dopamine, Barbital, Talbutal, Barbituric-acid-derivative, Aprobarbital,
Adinazolam, Butalbital, Glycine, Galantamine, Lorazepam, Quazepam,
Clotiazepam, Flurazepam, L-Glutamic-Acid, Temazepam, Methylphenobarbital,
Primidone, Butethal, Butabarbital, Pentobarbital, Amobarbital, Midazolam,
Halothane, Amoxapine, Vitamin-E, Metharbital, Secobarbital, Phenobarbital,
Clonazepam, Clobazam, Fludiazepam, Chlordiazepoxide, Bromazepam,
Thiopental, Eletriptan, Estazolam, Triazolam, Alprazolam,
Prazepam, Succinic-acid, Diazepam, Cinolazepam, Clorazepate
Cluster 2 Ropinirole, Olanzapine, Promazine, Lisuride, Pramipexole, Disopyramide,
Minaprine, Clozapine, Droxidopa, Carvedilol, Apomorphine, Epinephrine,
Promethazine, Yohimbine, Nortriptyline, Sertindole, Aripiprazole, Pergolide,
Quetiapine, Norepinephrine, Bromocriptine, Acepromazine, Chlorpromazine,
Trimipramine, Chlorprothixene, Cabergoline, Methotrimeprazine, Ziprasidone,
Propiomazine, Thioridazine, Amitriptyline, Doxepin, Thioproperazine,
Paliperidone, Maprotiline, Desipramine, Risperidone, Ergotamine, Imipramine
Cluster 3 Trastuzumab, Basiliximab, Adalimumab, Tositumomab, Alemtuzumab,
Muromonab, Alefacept, Natalizumab, Rituximab, Etanercept,
Gemtuzumab-ozogamicin, Ibritumomab, Bevacizumab, Cetuximab,
Palivizumab, Daclizumab, Abciximab, Efalizumab
Cluster 4 Alpha-D-Mannose, Coagulation-Factor-IX, Vitamin-C, Urokinase, Marimastat,
Antihemophilic-Factor, Menadione, Benzamidine, Drotrecogin-alfa, L-Carnitine,
Tenecteplase
Cluster 5 Heme, Famoxadone, 5-n-undecyl-6-hydroxy-4-7-dioxobenzothiazole,
Ubiquinone-2, Minocycline, 2-Nonyl-4-hydroxyquinoline-N-oxide,
NADH
Cluster 6 Staurosporine, Sorafenib, Imatinib, Dasatinib, Palifermin, Sunitinib,
Adenosine-triphosphate
Cluster 7 Icosapent, Acitretin, Alitretinoin, Sulfasalazine, Genistein
Cluster 8 Paroxetine, Tramadol, Pseudoephedrine, Ephedra, Methamphetamine
Cluster 9 Nefazodone, Clomipramine, Cocaine, 3-4-Methylenedioxymethamphetamine
Cluster 10 Puromycin, Cladribine, Alpha-Hydroxy-Beta-Phenyl-Propionic-Acid,
Anisomycin
Cluster 11 Amlodipine, Nimodipine, Mibefradil
Cluster 12 Verapamil, Nifedipine
Cluster 13 Hydroflumethiazide, Zonisamide
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Table 4: 10 highest-ranked drug target proteins predicted for each cluster shown in table
3.
Cluster ID Predicted drug target proteins
Cluster 1 HTR3A,CHRNE,CHRNG,CHRND,FXYD1,CRELD2,GPR26,HAAO,
GRID2IP,CLIC6
cluster 2 ADORA1,ADORA2A,GRIN2A,GRIN2B,EDNRA,CHRNA4,CHRNA3,
CACNA1C,P2RX4,TACR1
cluster 3 DPP4,CCL5,TFRC,CD86,PVRL1,F2,VCAM1,ADIPOQ,CR2,IL1B
cluster 4 APOE,THBS1,ALS2,FGB,ANXA1,C4BPB,TGFB1,SERPINA10,MGST3,GAS
cluster 5 CYP1A1,FH,PDK4,CYP2C9,CYP2C19,CYP1A2,CYB5R1,PC,CYP2E1,FDX1
cluster 6 FRAP1,ACVR2A,ACVR2B,ENG,AKT2,ACVR1C,ABCB4,TGFBR2,
CFTR,BMPR2
cluster 7 CTNNB1,BAAT,IRX4,ALOX5AP,REXO4,XPMC2H,TRIM59,TRPV2,
SLC30A9,ZNF398
cluster 8 SLC6A1,DRD4,DRD2,DRD1,DRD3,BCL2,OXTR,DNAJB4,NDUFB10,ABR
cluster 9 HTR1B,SLC6A1,DRD2,DRD3,GRIN2A,OXTR,DRD1,BCL2,PSEN1,CHRNB2
cluster 10 RPS11,RPS7,RPL35,RPL32,MRPS5,RPL36A,RPL30,RPS13,RPL34,RPL29
cluster 11 CACNA1A,RYR1,KCNMA1,CACNG2,CACNA1E,SLC8A1,CACNA2D4,
CATSPER1, KCNJ12,SCN8A
cluster 12 KCNMA1,RYR1,CACNA1E,CACNA2D4,KCNA2,KCNH1,ALG10B,KCR1,
KCNIP2,KCNQ1
cluster 13 KCNJ12,CACNA1A,SLC8A1,SCN10A,CACNA1S,SCN8A,CA9,CACNA1C,
KCNQ1,CACNB2
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7. Figures
28
Figure 1: HDN Edge Distribution. The X axis shows the 39800 edges in the HDN and
the Y axis shows, for each edge di → dj , the average rank of the seed proteins of dj (the
smaller, the better). There are two turning points in the curve, roughly at 3% and 86%
of all edges.
29
Figure 2: Pruned Human Drug Network including only 1328 highest relationship (3% of
the original network). The biological significance of the observed findings is discussed in
Section 4.2.
30
Figure 3: Clustering the pruned HDN using MCL Algorithm [64]. Section 4.2 discusses
the clusters in details.
31
Figure 4: Comparing Individual approach with Network approach with respect to average
rank of seed proteins (The smaller, the better). The Network approach outperforms the
Individual approach in clusters 2, 6, 10 and 12 with 39, 7, 4 and 2 drug members.
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